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vide information regarding efficacy, because it 
was underpowered for a mortality effect; morbid-
ity also was not reported. Furthermore, since our 
studies in the medical and the surgical ICU have 
shown that survival curves separated only after 
30 days or more, studies aiming for an early mor-
tality benefit would predictably fail.
Sustained blood-glucose control in patients 
with diabetes2 or critical illness prevents the cel-
lular damage inflicted by hyperglycemia, a benefit 
that outweighs the risk of hypoglycemia. Con-
tinuous glucose-monitoring systems are await-
ed, which could further reduce episodes of hypo-
glycemia and hyperglycemia. Current data support 
careful maintenance of normoglycemia in all pa-
tients in the ICU, from admission on.
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The Editorialist replies: Tamler et al. suggest 
that we should overlook the excess mortality po-
tentially associated with short-term intensive in-
sulin therapy in the study by Van den Berghe et 
al. The excess early deaths in the intensive-treat-
ment group could have a substantial effect on both 
1.
2.
the subgroup analyses of patients with long stays 
in the medical ICU and on morbidity. The assign-
ment to subgroups after randomization is prob-
lematic, since patients were considered to have a 
long stay in the ICU on the basis not just of ran-
domization but also of survival during the first 
three days in the ICU. Thus, the results for those 
with long stays may reflect true benefits of inten-
sive insulin therapy or survivor effects before 
these patients were included in the subgroup (i.e., 
the sickest patients died before being included). 
The morbidity data in the intention-to-treat analy-
sis are exciting but difficult to interpret because 
of the differential time to death — early deaths 
in the intensive insulin group could effectively 
protect against the development of renal failure 
and prolonged use of mechanical ventilation. My 
opinion regarding target therapeutic values of glu-
cose is based on published international consen-
sus,1 since the data available from randomized 
trials are equivocal (one positive phase 2 study, 
one negative phase 2 study, and the reportedly 
negative multicenter Efficacy of Volume Substitu-
tion and Insulin Therapy in Severe Sepsis [VISEP] 
study2).
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Long-Term Outcome of Renal Transplantation 
from Older Donors
To the Editor: We have used an approach simi-
lar to that of Remuzzi et al. (Jan. 26 issue)1 in the 
assessment of kidneys from donors older than 60 
years of age and the implantation of organs with 
minimal renal changes as assessed on biopsy be-
fore transplantation. During a three-year period, 
we performed 150 renal biopsies (with a mean of 
80 glomeruli obtained per biopsy) of kidneys 
from 75 cadaveric donors 61 through 84 years of 
age. A pathologist evaluated the biopsy specimens 
using strict, objective, blinded criteria (as discussed 
by Karpinski et al.2).
Kidneys of cadaveric donors in their 60s were 
adequate for single transplantation 44.1 percent 
of the time (total score, 0 to 3, according to the 
scoring system used by Karpinski et al.) and for 
dual transplantation 35.2 percent of the time (total 
score, 4 to 6). Kidneys from cadaveric donors 70 
through 80 years of age were adequate for single 
and dual transplantation in 40.5 percent and 35.1 
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percent of cases, respectively. Our data confirm 
that preimplantation biopsy of kidneys from older 
cadaveric donors may be useful for increasing the 
number of kidneys available for transplantation.
Maria Rosaria Raspollini, M.D., Ph.D.
Luca Messerini, M.D.
Gian Luigi Taddei, M.D.
University of Florence
50134 Florence, Italy
mariarosaria.raspollini@unifi.it
Remuzzi G, Cravedi P, Perna A, et al. Long-term outcome of 
renal transplantion from older donors. N Engl J Med 2006;354:
343-52.
Karpinski J, Lajoie G, Cattran D, et al. Outcome of kidney 
transplantation from high-risk donors is determined by both 
structure and function. Transplantation 1999;67:1162-7.
To the Editor: The methods of Remuzzi et al. 
do not justify the conclusions the authors reached. 
A major limitation of their study is that the ma-
jority of the patients were recipients of dual al-
lografts, whereas only eight patients received sin-
gle allografts. An appropriate control group would 
have been recipients of dual kidneys from older 
donors without preimplantation biopsy. In the 
Cox regression model the authors used, preimplan-
tation biopsy was included as an independent fac-
tor, but not whether the transplant was dual as 
compared with single. The appropriate conclu-
sions seem to be that the rate of graft survival for 
dual allografts from older donors matches that 
for single allografts from donors 60 years old or 
younger and is better than that for single allografts 
from older donors. These conclusions are not new, 
since it has already been demonstrated that re-
cipients of dual kidneys from donors selected with 
the use of expanded criteria for donation do as 
well as recipients of single kidneys from donors 
selected with standard criteria.1
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nors: a long-term follow-up. Transplantation 2004;78:692-6.
To the Editor: In the study by Remuzzi et al., 
graft survival for kidneys from older cadaveric 
donors that are allocated on the basis of histologic 
evaluation approached the rate for kidneys from 
1.
2.
1.
younger donors. However, all methods of histo-
logic evaluation of donor kidneys are not equiva-
lent. Remuzzi et al. examined specimens obtained 
by core needle biopsy, as opposed to wedge biopsy, 
which is used in many centers with more variable 
results.1-4 Core biopsy samples the full cortical 
thickness, including arteries near the corticome-
dullary junction. In contrast, wedge-biopsy spec-
imens often lack these vessels and frequently over-
represent the superficial cortex, with the greatest 
degree of glomerular and tubulointerstitial scar-
ring in older people.
Remuzzi et al. report no graft losses resulting 
from biopsies performed with 16-gauge needles; 
they also report equivalent median cold-ischemia 
times for kidneys that were biopsied and those 
that were not biopsied. Thus, the use of histologic 
evaluation (if it is performed on core-biopsy speci-
mens) in the assessment of kidneys from donors 
selected with the use of extended criteria should 
markedly reduce variability in the prediction of 
outcome.
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To the Editor: Remuzzi et al. suggest that a 
strategy based on histologic evaluation of kid-
neys from older donors improves outcome while 
expanding the donor pool. However, the data are 
inconclusive.
First, it appears that patients in the positive-
reference group (who received single kidney trans-
plants from donors 60 years of age or younger) 
were recruited from various transplantation cen-
ters without matching for retransplantation, panel-
reactive antibodies, and immunosuppressive ther-
1.
2.
3.
4.
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apy. Moreover, the shorter waiting time of the 
patients in the study group, which is explained 
by their preferential position on the waiting list, 
might have biased the results.1
Second, there is no evidence supporting ex-
pansion of the donor pool. The numbers of dis-
carded kidneys in the study and reference groups 
are not provided, and in their presentation of 
data, the authors do not take into account that 
more patients remain on dialysis if dual trans-
plantation is performed. If such potential patients 
are included in the analysis, the proposed strat-
egy results in more patients who remain on di-
alysis (Table 1). Such patients would be harmed, 
since the life expectancy of patients receiving di-
alysis is worse than that of graft recipients, even 
when the kidney comes from a donor selected 
with the use of expanded criteria for donation.2
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The authors reply: We observed that a strategy 
based on histologic evaluation of kidneys from 
older donors improves outcome while expanding 
the donor pool. Hilbrands and Wetzels suggest 
that our data might be confounded by positive-
reference recipients recruited from various cen-
ters. We addressed this concern with an additional 
analysis of the outcome of recipients of grafts 
from older donors that had undergone histologic 
evaluation and of age-matched and sex-matched 
recipients in the positive-reference group, with 
both groups of patients coming from two centers 
of the Double Kidney Group network. Graft sur-
vival in the two cohorts was similar.
The shorter waiting time in the study group 
is explained not by the preferential position on 
the waiting list but, rather, by the expansion of the 
donor pool, which enhanced the chance of re-
transplantation and was an additional advantage 
of our proposed strategy. Twenty-four percent of 
donors of kidneys that were biopsied were more 
than 74 years old. Kidneys from donors older than 
1.
2.
74 years of age were never used for transplanta-
tion without preimplantation biopsy. Thus, our 
strategy actually translates into an expansion of 
the donor pool. This is a major advantage for pa-
tients on waiting lists, and this issue is not con-
sidered in the table provided by Hilbrands and 
Wetzels. They are correct in saying that more pa-
tients remain on dialysis if dual transplantations 
are performed. However, they do not mention that 
patients who return to dialysis after undergoing 
transplantation have a higher death rate than do 
patients receiving dialysis who have not undergone 
transplantation, a fact that should be considered 
in their calculations.1
Our mathematical modeling indicates that 
for 100 patients on a waiting list, at 10 years there 
will be 3 deaths among recipients of grafts that 
have undergone histologic evaluation and 11 
deaths among recipients of grafts that have not 
undergone histologic evaluation (Fig. 1). At the 
same time, the numbers of patients who are 
predicted to be alive with a functioning kidney 
are similar in the two groups (45 and 43, respec-
tively).
In the series by Tan and colleagues2 cited by 
Panesar et al., the two-year rate of graft survival 
(82.1 percent) was less than that in our series (94 
Table 1. Effects of Histologic Evaluation of Donor Kidneys.*
Variable Donor Age >60 Yr
Histologic 
Evaluation
No Histologic 
Evaluation
number
Donors 58 58
Kidneys available for transplantation 116 116
Patients receiving dialysis on waiting list 116 116
Results after transplantation
Patients receiving grafts 62 116
Patients remaining on dialysis 54 0
Patients who died 3 (plus 4)† 9
Patients back on dialysis 4 27
End of observation
Patients alive with functioning graft 55 80
Patients on dialysis 54 27
* Calculations are based on the number of patients in Table 2 of the study 
by Remuzzi et al.
† It is assumed that the death rate of patients receiving dialysis was at least 
the same as that of graft recipients in the control group.
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percent), despite a younger mean age of donors 
(61±1 vs. 69±8, respectively). Other series of dual 
transplantations without histologic evaluation 
report even lower rates of survival.3 Moreover, the 
systematic use of kidneys from older donors for 
dual transplantation would unnecessarily reduce 
the number of transplantations. Raspollini et al. 
correctly report that some 40 percent of kidneys 
that are harvested from donors older than 60 years 
of age appear to be adequate for single transplan-
tation on the basis of histologic evaluation. We 
agree with Haas et al. that core biopsy markedly 
reduces variability in the prediction of outcome 
for recipients of renal transplants.
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Figure 1. Projected Deaths during a 10-Year Follow-up Period for 100 Patients on a Waiting List for Kidney Transplants. 
Projections are made according to the use of kidneys from donors older than 60 years for single or dual transplanta-
tion on the basis of the histologic-evaluation score and for single transplantation without histologic evaluation. Data 
have been adjusted to include a projected 24 percent increase in the number of available donors (resulting from the 
use of biopsy-based histologic evaluation) and similar death rates among patients who receive a transplant, who re-
main on dialysis, or who return to dialysis after their transplant has failed. In the equation, x denotes time, y number, 
and Ln(x) the natural logarithm of time. 
Tumor Necrosis Factor α in Refractory Asthma
To the Editor: In our opinion, the randomized 
clinical trial by Berry et al. (Feb. 16 issue)1 ap-
pears to mitigate the excitement that has been 
generated in recent years concerning the use of 
tumor necrosis factor α (TNF-α) inhibitors in the 
management of refractory asthma.2 In an open-
label study,3 12 weeks of treatment with etaner-
cept resulted in a substantial improvement in 
symptoms; all but one of the patients were able 
to discontinue the use of bronchodilators. By con-
trast, the observed statistically significant improve-
ment in quality-of-life and symptom scores in the 
trial by Berry et al. is probably not of clinical rele-
vance, and none of the patients could discontinue 
or reduce the use of nebulized or oral treatment.
Examination of the individual quality-of-life 
scores and comparison of the data obtained in 
the placebo and etanercept treatment periods sug-
gest that only two patients would unambigu-
ously benefit from this expensive treatment. It is 
unfortunate that it was not possible to dissect 
out from the data presented any specific charac-
teristics that would clearly identify those who 
would have a response to etanercept. In our opin-
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